1-4 of 4
Alexander Dew, DO
Close
Sort by
Journal Articles

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

Emily Bryer, DO, Alexander Dew, DO, MS, Elizabeth Hill, MD, Elizabeth Gil Ramirez, MD, Candis Morrison, CNP, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Kevin Camphausen, MD, Jennifer Jones, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-136176
Published: 2020
Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136182
Published: 2020
Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Dickran Kazandjian, MD, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Neha Korde, MD, Sham Mailankody, MBBS, Elisabet E. Manasanch, MD, Mary L. Kwok, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Yong Zhang, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Crystal Lu, PharmD, BCOP, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Peter Choyke, MD, Alina Dulau-Florea, MD, Esther Mena, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Nisha Patel, DO, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, Seth M. Steinberg, PhD, William D. Figg, PhD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136148
Published: 2020
Journal Articles

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Elizabeth Hill, MD, Neha Korde, MD, Sham Mailankody, MBBS, Candis Morrison, CNP, PhD, Alexander Dew, DO, Jennifer Hsu Albert, RN, Katherine Graap, RN, Francesco Maura, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1794.
https://doi.org/10.1182/blood-2019-126952
Published: 2019